Tazicef Powder For Solution For Injection 1G Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Tazicef: Powder for solution for injection (1g)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


In-Depth Information
Select a Medication

Tazicef 1g Powder for Injection

NDC: 004095082
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Bacteremia, Pelvic Cellulitis, Peritonitis, Pneumonia, Meningitis, Intraabdominal Infections, Septicemia, Bone And Joint Infections, Nosocomial Pneumonia, Gynecologic Infections, Skin And Skin Structure Infections, Urinary Tract Infection (UTI), Endometritis, Lower Respiratory Tract Infections

Sometimes used for but not FDA approved for the following conditions:
Febrile Neutropenia, Bronchiectasis, Pneumonia Prophylaxis, Melioidosis

Storage Information
Protect from light
Store at controlled room temperature (between 68 and 77 degrees F)
Tazicef 1g Powder for Injection

Reported Side Effects for Tazicef 1g Powder for Injection

No White Blood Cells Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Cholestasis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Yellow Skin Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Convulsions Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Breathing Difficulties Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Lightheadedness Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Injection Site Reaction Incidence:
<2.0%*
Severity: MILD
Onset: RAPID
Kidney Inflammation Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
High Lymphocytes Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Paresthesias Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Irritated Blood Vessels Incidence:
<2.0%*
Severity: MODERATE
Onset: RAPID
Yeast Infection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Hemolytic Anemia Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Low White Blood Cells Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Angioedema Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Pseudomembranous Colitis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Vaginal Infection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
0.2%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
0.2%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
0.6%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
1.3%*
Severity: MILD
Onset: EARLY
Fever Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Rash With Pustules Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Itching Incidence:
2.0%*
Severity: MILD
Onset: RAPID
High Platelet Count Incidence:
2.2%*
Severity: MODERATE
Onset: DELAYED
Eosinophilia Incidence:
7.7%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Tazicef

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5